Saudi Arabia – Healthcare, Regulatory and Reimbursement Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Saudi Arabia pharmaceutical market was valued at $10.2 billion in 2020. The market will grow at a CAGR of more than 6% from 2020 to 2026. The Saudi Arabia medical devices market was valued at $4.8 billion in 2021 and is expected to grow at a CAGR of more than 4% from 2021 to 2027. Saudi Arabia is one of the most attractive economies in the Middle East and North Africa (MENA) in terms of healthcare and regulatory reforms, skilled workforce, and government support for public-private partnerships.

Overview of the Saudi Arabia pharmaceuticals market

Overview of the Saudi Arabia pharmaceuticals market

For more insights on this report, download a free report sample

Overview of the Saudi Arabia medical devices market

Overview of the Saudi Arabia medical devices market

For more insights on this report, download a free report sample

What are the market dynamics in the Saudi Arabia pharmaceuticals market?

In 2020, as per the United Nations E‑Government Survey, Saudi Arabia was ranked 43rd in the E-Government Development Index, and 66th in E-Participation Index. In 2021, the country was ranked 66th in the World Intellectual Property Organization’s Global Innovation Index and 61 in the GHS Index Country Profile. The population of Saudi Arabia is projected to increase from 34.81 until 2060. The increasing population is expected to fuel the demand for healthcare services in the KSA. Saudi Arabia is the largest spender on healthcare across the MENA region. The increase in Saudi Arabian pharmaceutical market size is attributed to the growing population, increased per capita healthcare spending, and preference for research-based pharmaceutical products.

What are the major segments in the Saudi Arabia pharmaceuticals market?

The pharmaceuticals market in Saudi Arabia can be segmented into generics, biologics, biosimilars, and over the counter (OTC). Saudi Arabia has many opportunities in biologics with a primary focus on insulin analogs, autoimmune disease therapies, pandemic response, and oncology. Biosimilars are also accessible and affordable in Saudi Arabia.

Saudi Arabia pharmaceuticals market, by segment

Saudi Arabia pharmaceuticals market, by segment

For more segment insights, download a free report sample

Who are the major players in the Saudi Arabia pharmaceuticals market?

The key players in the pharmaceuticals market in Saudi Arabia are Novartis, GlaxoSmithKline (GSK), Pfizer, Saudi Pharmaceutical Industries and Medical Appliance Corp (SPIMACO), and Tabuk Pharmaceuticals. 

Novartis

It is a global healthcare company based in Basel, Switzerland. It operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. In Saudi Arabia, it operates out of Dammam and Riyadh. Novartis mainly deals with consumer healthcare, pharmaceuticals, and medical devices.

GSK

It is a healthcare company that focuses on the development, manufacture, and commercialization of pharmaceuticals, vaccines, and consumer healthcare products. It offers drugs for the treatment of respiratory diseases, cancer, cardiovascular diseases, HIV, infectious diseases, immuno-inflammation, and rare diseases. In Saudi Arabia, it operates out of Jeddah.

Pfizer

It is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes drugs for various conditions, consumer healthcare products, generics, and APIs. Pfizer’s Saudi Arabia offices are in King Abdullah Economic City.

Saudi Arabia pharmaceuticals market, by key players

Saudi Arabia pharmaceuticals market, by key players

To know more about key players, download a free report sample

What are the market dynamics in the Saudi Arabia medical devices market?

The Saudi Arabia medical devices market has well-regulated consistent demand from focused buyers (National Unified Procurement Company and Gulf Health Council). As of January 2022, there are more than 45 local medical devices manufacturers with a significant contribution of 6% market share. By 2025, the goal is to increase the local manufacturer’s market share percentage by expanding the current product portfolio and attracting new medical devices technologies to provide comprehensive solutions needed by healthcare providers. This will ultimately reflect on the diversity of products and the number of factories established during this period.

What are the key segments in the Saudi Arabia medical devices market?

The medical devices market in Saudi Arabia can be segmented into hospital supplies, general surgery, anesthesia and respiratory devices, orthopedic devices, and cardiovascular devices. Hospital supplies accounts for more than 60% of the revenue in the market and is expected to expand at a CAGR of more than 3% from 2021 to 2025.

Saudi Arabia medical devices market, by segment

Saudi Arabia medical devices market, by segment

For more segment insights, download a free report sample

Who are the major players in the Saudi Arabia medical devices market?

The major players in the medical devices market in Saudi Arabia are Fujitsu, Medtronic, AstraZeneca, Kimberly-Clark and GE Healthcare.

Fujitsu

They provide information and communications technology (ICT) solutions. The company serves a wide range of customers across automotive, financial, retail, telecommunications, life-science, and healthcare markets. Fujitsu is headquartered in Tokyo, Japan, and its Saudi Arabia operations center is in Jeddah.

Medtronic

It is a medical technology company which provides a wide range of medical devices for the treatment of heart disease, spinal conditions, neurological disorders, vascular disease, orthopedic disorders, and diabetes. Medtronic is headquartered in Dublin, Ireland. Medtronic’s footprint is in the Central and Eastern Europe, Middle East and Africa (CEMA) region. In Saudi Arabia, Medtronic is in Riyadh.

AstraZeneca

It is a biopharmaceutical company. Its product portfolio includes biologics, prescription pharmaceuticals, and vaccines. The company operates in Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK. The company operates in Riyadh, Saudi Arabia.

Saudi Arabia medical devices market, by key players

Saudi Arabia medical devices market, by key players

To know more about key players, download a free report sample

Saudi Arabia pharmaceuticals market report scope

Market size (2020) $10.2 billion
Growth rate CAGR of >6% from 2020 to 2026
Base year for estimation 2020
Key segments Generics, Biologics, Biosimilars, and Over the Counter (OTC)
Key players Novartis, GlaxoSmithKline (GSK), Pfizer, Saudi Pharmaceutical Industries and Medical Appliance Corp (SPIMACO), and Tabuk Pharmaceuticals

Saudi Arabia medical devices market report scope

Market size (2021) $4.8 billion
Growth rate CAGR of >4% from 2021 to 2027
Base year for estimation 2021
Key segments Hospital Supplies, General Surgery, Anesthesia and Respiratory Devices, Orthopedic Devices, and Cardiovascular Devices
Key players Fujitsu, Medtronic, AstraZeneca, Kimberly-Clark, and GE Healthcare

This report provides:

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.
  • Profiles and SWOT analysis of the major players in the pharmaceutical market: Novartis, GlaxoSmithKline, Pfizer, Tabuk, and SPIMACO.
  • Profiles and SWOT analysis of the major players in the medical device market: Fujitsu, Medtronic, AstraZeneca, Kimberly Clark, and GE Healthcare.
  • An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in the healthcare market, HealthTech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices.
  • Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure, and healthcare expenditure.
  • An overview of the opportunities for and challenges to growth in the Saudi Arabian healthcare market.

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the Saudi Arabian healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact Saudi Arabian healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
  • Organize sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights: Facts about the Saudi Arabia Healthcare Market

2.3 Key Highlights: Healthcare Startups in Saudi Arabia

2.4 Key Events: Saudi Arabia Pharmaceutical News, 2015–2021

2.5 Key Events: Saudi Arabia Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020–2021

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, Saudi Arabia, 2021

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Saudi Arabia

3.5 Pharmaceutical Market – Market Segments

3.6 COVID-19 Epidemiology, Saudi Arabia

3.7 COVID-19 Impact and Developments, Saudi Arabia

3.8 COVID-19 Impact and Developments in the Healthcare Market, Saudi Arabia

3.9 COVID–19 Clinical Trials Landscape, Saudi Arabia

3.10 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Saudi Arabia, 2019–2021

6.2 Deal Analysis: Medical Device Market, Saudi Arabia, 2019–2021

7. HealthTech Landscape

7.1 HealthTech Landscape, Saudi Arabia

7.2 HealthTech Deals Landscape, Saudi Arabia

7.3 Key HealthTech Deals, Saudi Arabia

7.4 Adoption of Technology in Healthcare, Saudi Arabia

7.5 Digital Statistics, Saudi Arabia

7.6 Digital Regulations, Saudi Arabia

7.7 HealthTech Landscape: Benefits and Risks, Saudi Arabia

8. Market Access

8.1 Overview of Healthcare System, Saudi Arabia

8.2 Reimbursement Process, Saudi Arabia

8.3 Overview of Insurance Providers, Saudi Arabia

8.4 Out-of-Pocket Spending and Pharmaceutical Price Index, Saudi Arabia

8.5 Pricing Policies, Saudi Arabia

8.6 Regulatory Landscape, Saudi Arabia

8.6.1 Overview of Regulatory Agencies, Saudi Arabia

8.6.2 Marketing Authorization for Pharmaceutical Products, Saudi Arabia

8.6.3 Marketing Authorization for Biologics and Biosimilars, Saudi Arabia

8.6.4 Marketing Authorization for Medical Devices, Saudi Arabia

8.6.5 Pharmaceutical Exports and Imports Regulations, Saudi Arabia

8.6.6 Intellectual Property Rights, Patent, Saudi Arabia

8.6.7 Intellectual Property Rights, Trademark, Saudi Arabia

8.6.8 Clinical Trial Regulations, Saudi Arabia

8.6.9 Pharmaceutical Clinical Trials Landscape, Saudi Arabia

8.6.10 Medical Devices Clinical Trials Landscape, Saudi Arabia

8.6.11 Pharmacy License Regulations, Saudi Arabia

8.6.12 Pharmaceutical Advertising Regulations, Saudi Arabia

8.6.13 Labeling and Packaging Regulations, Saudi Arabia

9. Country Healthcare Landscape

9.1 Saudi Arabian Healthcare Policy Highlights

9.2 Healthcare Facilities, Saudi Arabia

9.3 Healthcare Parameters, Saudi Arabia

9.4 Life Expectancy and Immunization Rate, Saudi Arabia

9.5 Environmental Health, Saudi Arabia

9.6 Healthcare Personnel, Saudi Arabia

9.7 Disease Burden, Saudi Arabia

9.8 Healthcare Expenditure, Saudi Arabia

10 Trade Associations, Saudi Arabia

11 Trade Fairs, Saudi Arabia

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Approved biosimilars, Saudi Arabia, 2020

Table 2: Opportunities in pharmaceutical and biotech clusters, Saudi Arabia, 2021

Table 3: Top 10 selling biopharma drugs, Saudi Arabia, 2021

Table 4: COVID-19 indicators, Global and Saudi Arabia, 2022

Table 5: Available COVID-19 IVD products, Saudi Arabia, 2020–2021

Table 6: Pipeline COVID-19 IVD products, Saudi Arabia, 2020–2021

Table 7: Authorized COVID-19 vaccines, Saudi Arabia, 2020–2021

Table 8: Medical devices market, major segments ($M), Saudi Arabia, 2020

Table 9: Health insurance market, market share (%), Saudi Arabia, 2021

Table 10: Pharmaceutical approval timelines, Saudi Arabia, 2019

Table 11: MDMA evaluation fees, Saudi Arabia, 2021

Table 12: License or renewal fee ($), Saudi Arabia, 2019

Table 13: Profit margin (%), Saudi Arabia, 2019

Table 14: Customs ports, Saudi Arabia, 2021

Table 15: Patent fees ($), Saudi Arabia, 2021

Table 16: Trademark fees ($), Saudi Arabia, 2019

Table 17: Label of a pharmaceutical product, Saudi Arabia, 2021

Table 18: Minimum particulars to appear on blisters or strips, Saudi Arabia, 2021

Table 19: Minimum particulars to appear on small immediate packaging, Saudi Arabia, 2021

Table 20: Label of a pharmaceutical product, Saudi Arabia, 2021

Table 21: Recommendations for primary packaging, Saudi Arabia

Table 22: Recommendations for secondary packaging, Saudi Arabia

Table 23: Trade Fairs, Saudi Arabia, 2022

Figures

Figure 1: Pharmaceutical market, revenue ($B and SARB), Saudi Arabia, 2013–2020

Figure 2: Medical devices market, revenue ($B), Saudi Arabia, 2016–2021

Figure 3: Healthcare startups in Saudi Arabia, 2022

Figure 4: Country profile, Saudi Arabia, 2022

Figure 5: Pharmaceutical market, revenue ($B), Saudi Arabia, 2013–2020

Figure 6: Pharmaceutical market, revenue forecast ($B), Saudi Arabia, 2021–2026

Figure 7: Pharmaceutical exports ($M), South Arabia, 2011–2020

Figure 8: Top export partners, Saudi Arabia, 2020

Figure 9: Pharmaceutical imports ($B), Saudi Arabia, 2011–2020

Figure 10: Top import partners, Saudi Arabia, 2020

Figure 11: Pharmaceutical supply chain, Saudi Arabia, 2022

Figure 12: Drug track and trace system, Saudi Arabia, 2022

Figure 13: Innovation centers, Saudi Arabia, 2021

Figure 14: Major OTC drug classes (share %), Saudi Arabia, 2018

Figure 15: COVID-19 (number of cases), Saudi Arabia, 2020–2022

Figure 16: COVID-19 (number of deaths), Saudi Arabia, 2020–2022

Figure 17: COVID-19-related travel restrictions, Saudi Arabia, 2020–2021

Figure 18: COVID-19 fiscal stimulus timeline, Saudi Arabia, 2020–2021

Figure 19: COVID-19 vaccine dose administration, number of vaccine doses administered, Saudi Arabia, 2021–2022

Figure 20: COVID-19 clinical trials sponsors by count, Saudi Arabia, 2020–22

Figure 21: COVID-19 clinical trials count by phase, Saudi Arabia, 2020–2022

Figure 22: COVID-19 clinical trials count by trial status, Saudi Arabia, 2020–2022

Figure 23: Medical devices market, revenue ($B), Saudi Arabia, 2016–2021

Figure 24: Medical devices market, revenue forecast ($B), Saudi Arabia, 2022–2027

Figure 25: Medical devices market, major segments (%), Saudi Arabia, 2020

Figure 26: Hospital supplies market, revenue ($B), Saudi Arabia, 2017–2025

Figure 27: General surgery market, revenue ($M), Saudi Arabia, 2017–2025

Figure 28: Orthopedic devices, revenue ($M), Saudi Arabia, 2017–2025

Figure 29: Cardiovascular devices, revenue ($M), Saudi Arabia, 2017–2025

Figure 30: Anesthesia and respiratory devices, revenue ($M), Saudi Arabia, 2017–2025

Figure 31: Diagnostic market, revenue ($M), Saudi Arabia, 2016–2021

Figure 32: Diagnostic market, revenue ($M), Saudi Arabia, 2022–2027

Figure 33: Medical devices market, revenue ($B) of major companies, Saudi Arabia, 2020

Figure 34: Deals value and deal count, pharmaceutical market, Saudi Arabia, 2019–2022

Figure 35: Deals value and deal count, subtypes, pharmaceutical market, Saudi Arabia, 2019–2022

Figure 36: Deals value and deal count, quarterly, pharmaceutical market, Saudi Arabia, 2019–2022

Figure 37: Top therapy areas by deal value ($M), pharmaceutical market, Saudi Arabia, 2019–2022

Figure 38: Top therapy areas by deal count, pharmaceutical market, Saudi Arabia, 2019–2022

Figure 39: M&A deals by quarter, pharmaceutical market, Saudi Arabia, 2019–2022 (by value and by number)

Figure 40: Deals value and deal count, medical devices market, Saudi Arabia, 2019–2022

Figure 41: Deals value and deal count, subtypes, medical devices market, Saudi Arabia, 2019–2022

Figure 42: Deals value and deal count, quarterly, medical devices market, Saudi Arabia, 2019–2021

Figure 43: Top equipment sectors by deal value ($M), medical devices market, Saudi Arabia, 2019–2022

Figure 44: Top equipment sectors by deal count, medical devices market, Saudi Arabia, 2019–2022

Figure 45: M&A deals by quarter, medical devices market, Saudi Arabia, 2019–2022 (by value and by number)

Figure 46: e-health strategy supporting MOH goals, Saudi Arabia, 2021

Figure 47: Digital health strategy, mission and vision, Saudi Arabia, 2021

Figure 48: Key objectives, digital health strategy, Saudi Arabia, 2021

Figure 49: Organizational chart, digital health governance, Saudi Arabia, 2021

Figure 50: Deals value ($M), healthTech, Saudi Arabia, 2019–2022

Figure 51: Deal count (number of deals), healthtech, Saudi Arabia, 2019–2022

Figure 52: Digital technology, Saudi Arabia, 2022

Figure 53: Structural overview of healthcare sector, Saudi Arabia, 2021

Figure 54: Organizational chart of ministry of health, Saudi Arabia, 2021

Figure 55: National Healthcare Transformation Program (NHTP), Saudi Arabia, 2021

Figure 56: SFDA Strategic Plan (2018–2022) specifications, Saudi Arabia, 2021

Figure 57: Formulary additions, Saudi Arabia, 2021

Figure 58: Drug approval process, Saudi Arabia, 2021

Figure 59: National insurance system of GOSI, Saudi Arabia, 2021

Figure 60: Out-of-Pocket spending ($ per capita), Saudi Arabia, 2011–2021

Figure 61: Annual rate of change (%), health price index, Saudi Arabia, 2015–2021

Figure 62: SFDA, organizational structure, Saudi Arabia, 2021

Figure 63: MAA submission process, Saudi Arabia, 2021

Figure 64: Drug licensing, Saudi Arabia, 2021

Figure 65: Drug licensing renewal, Saudi Arabia, 2021

Figure 66: Process for designating a biosimilar for priority review, Saudi Arabia, 2021

Figure 67: Process for designating a novel drug for priority review, Saudi Arabia, 2021

Figure 68: Patent application process, Saudi Arabia, 2021

Figure 69: Pharmaceutical clinical trials count by trial status, Saudi Arabia, 2019–2022

Figure 70: Pharmaceutical clinical trials count by phase, Saudi Arabia, 2019–2022

Figure 71: Pharmaceutical clinical trials count by indication, Saudi Arabia, 2019–2022

Figure 72: Top five pharmaceutical clinical trials sponsors by count, Saudi Arabia, 2019–2022

Figure 73: Medical devices clinical trials count by trial status, Saudi Arabia, 2019–2022

Figure 74: Medical devices clinical trials count by indication, Saudi Arabia, 2019–2022

Figure 75: Medical devices clinical trials count by device category, Saudi Arabia, 2019–2022

Figure 76: Top five medical devices clinical trials sponsors by count, Saudi Arabia, 2019–2022

Figure 77: Number of hospitals (per 10,000 population), Saudi Arabia, 2016–2020

Figure 78: Hospital beds (per 1,000 population), Saudi Arabia, 2011–2017

Figure 79: Diagnostic equipment market, CT and MRI ($M), Saudi Arabia, 2015–2021

Figure 80: Diagnostic equipment market, mammography and nuclear imaging ($M), Saudi Arabia, 2015–2021

Figure 81: Immunization rate (%), Saudi Arabia, 2013–2019

Figure 82: Life expectancy at birth (years), Saudi Arabia, 2013–2019

Figure 83: CO2 emissions (million tons), Saudi Arabia, 2011–2018

Figure 84: PM2.5 (µg per m3), Saudi Arabia, 2010–2017

Figure 85: Physicians (per 1,000 population), Saudi Arabia, 2010–2016

Figure 86: Dentists (per 1,000 population), Saudi Arabia, 2016–2020

Figure 87: Nurses (per 1,000 population), Saudi Arabia, 2010–2018

Figure 88: Pharmacists (per 1,000 population), Saudi Arabia, 2010–2018

Figure 89: Major causes of mortality (per 100,000 population), Saudi Arabia, 2019

Figure 90: Major causes of male mortality (per 100,000 population), Saudi Arabia, 2019

Figure 91: Major causes of female mortality (per 100,000 population), Saudi Arabia, 2019

Figure 92: DALYs by major disease (per 100,000 population), Saudi Arabia, 2019

Figure 93: Healthcare expenditure as percentage of GDP (%), Saudi Arabia, 2011–2018

Figure 94: Health expenditure share (% of total health spending), Saudi Arabia, 2011–2018

Figure 95: Pharmaceutical spending (% of total health spending), Saudi Arabia, 2011–2018

Frequently asked questions

Saudi Arabia – Healthcare, Regulatory and Reimbursement Landscape thematic reports
Currency USD
$1,995

Can be used by individual purchaser only

$3,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Saudi Arabia – Healthcare, Regulatory and Reimbursement Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Saudi Arabia – Healthcare, Regulatory and Reimbursement Landscape in real time.

  • Access a live Saudi Arabia – Healthcare, Regulatory and Reimbursement Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.